Article
Author(s):
Patients with nephrolithiasis frequently have metabolic abnormalities that promote calculus formation and, when identified and corrected, may attenuate stone activity.
Coding Q&A: How to bill for second-generation stone device
Health policy in urology: 2024 AUA Advocacy Summit recap
Money Matters: How to cope with market volatility in 2025
How APPs can bridge the gap in urologist shortages
Level of service for vasectomy prompts coding confusion
Trends in urology: Arpeet Shah, MD, on challenges and opportunities in 2025
Expert discusses the promise of emerging MISTs for BPH
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk